References of "LIFRANGE, Eric"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLe cancer du sein en Belgique: pourquoi sommes-nous les premiers en Europe?
DESREUX, Joëlle ULg; Gaspard, Ulysse ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 231-7

Breast cancer incidence in Belgium is on the top of European countries, with 9.697 new cases in 2008 and 106/100.000 women/year. The explanation of this high incidence in our country is probably the ... [more ▼]

Breast cancer incidence in Belgium is on the top of European countries, with 9.697 new cases in 2008 and 106/100.000 women/year. The explanation of this high incidence in our country is probably the accumulation of risk factors (many of them are linked to lifestyle), and the impact of screening and registration of cases. The relative impact of each of theses factors is less clear because we don't have powerful statistical studies. Belgium is slightly above the European mean for breast cancer mortality, with 19,4/100.000 women/year and an all stages 15-year survival of 75%. Breast cancers are responsible for around 3% of all-cause mortality in Belgian women. This article discusses the causes of this high Belgian incidence and of current decrease of incidence in western countries, and reviews known and less known risk factors of breast cancers, with a special focus on menopause hormonal treatments. [less ▲]

Detailed reference viewed: 155 (11 ULg)
Full Text
Peer Reviewed
See detailReconstruction mammaire immédiate et radiothérapie post-opératoire : une mise au point
NARDELLA, Daniele ULg; LAUNGANI, Alexis ULg; LIFRANGE, Eric ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 368-361

La reconstruction mammaire est actuellement partie intégrante de la prise en charge du cancer du sein. Lorsqu’elle est proposée en immédiat, plusieurs contraintes se présentent au chirurgien plasticien ... [more ▼]

La reconstruction mammaire est actuellement partie intégrante de la prise en charge du cancer du sein. Lorsqu’elle est proposée en immédiat, plusieurs contraintes se présentent au chirurgien plasticien. La prise en charge des patientes devant bénéficier d’une mastectomie se complique par les traitements complémentaires de radiothérapie. Nous proposons, dans ce travail, une prise en charge multidisciplinaire des patientes en les adressant à des sous-groupes spécifiques. Une reconstruction immédiate sera proposée à certaines patientes compte tenu des traitements complémentaires par radiothérapie. Les choix d’orientation sont complexes et une littérature pauvre à ce sujet ne nous permet pas d’orienter de façon systématique toutes les patientes. De nouvelles études, notamment prospectives, sont nécessaires pour orienter les patientes désirant une reconstruction immédiate associée à une radiothérapie post-mastectomie. [less ▲]

Detailed reference viewed: 147 (0 ULg)
Full Text
Peer Reviewed
See detailLa chirurgie oncoplastique du sein.
BOUS, Aurélie ULg; NARDELLA, Daniele ULg; MAWEJA, Sylvie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 341-50

Oncoplastic surgery combines large lumpectomy and defect remodeling by different plastic surgery methods. These procedures improve the cosmetic result after partial mastectomy and widens the possibilities ... [more ▼]

Oncoplastic surgery combines large lumpectomy and defect remodeling by different plastic surgery methods. These procedures improve the cosmetic result after partial mastectomy and widens the possibilities for conservative treatment. Different techniques are used from simple glandular remodeling to more difficult techniques for breast plasties with or without simultaneous controlateral symetrisation procedure. The surgical option depends especially on the ratio between the volume of the tumor and the volume of the breast and the position of the tumor. This more effective conservative treatment facilitates also postoperative radiotherapy, reduces the sequellae and the psychological impact of breast cancer treatment. [less ▲]

Detailed reference viewed: 200 (15 ULg)
Full Text
Peer Reviewed
See detailPrise en charge des consequences de la carence oestrogenique apres cancer du sein.
BLERET, Valerie ULg; PINTIAUX, Axelle ULg; BELIARD, Aude ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 385-92

The prevention and the treatment of oestrogen deficiency induced by breast cancer treatments are crucial in the management of patients. The impacts of this deficiency must not be neglected: quality of ... [more ▼]

The prevention and the treatment of oestrogen deficiency induced by breast cancer treatments are crucial in the management of patients. The impacts of this deficiency must not be neglected: quality of life impairments inducing eventually premature withdrawal of hormonotherapies, and excess of bone and cardio-vascular morbidities and mortalities, especially in good prognosis young women. Management strategies of short and long term effects of this deficiency are reviewed and discussed here. [less ▲]

Detailed reference viewed: 109 (13 ULg)
Full Text
Peer Reviewed
See detailMastectomie bilaterale prophylactique chez les patientes a tres haut risque de cancer mammaire: au-dela de la technique...
BLERET, Valerie ULg; Cusumano, P.; DEZFOULIAN, Bahram ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 250-3

Bilateral prophylactic mastectomy is the most efficient risk management strategy for women at very high risk for breast cancer. Different methods can be used. The implementation of such a strategy must ... [more ▼]

Bilateral prophylactic mastectomy is the most efficient risk management strategy for women at very high risk for breast cancer. Different methods can be used. The implementation of such a strategy must respond to the request of a well informed patient. [less ▲]

Detailed reference viewed: 170 (9 ULg)
Full Text
Peer Reviewed
See detailGanglion sentinelle et sentibras: pour un "staging" axillaire sur mesure
Cusumano, P.; BLERET, Valerie ULg; Nos, C. et al

in Revue Médicale de Liège (2011), 66(5-6), 336-40

The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of removed lymph nodes is the most accurate method ... [more ▼]

The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of removed lymph nodes is the most accurate method for assessing spread of disease to these nodes. Axillary lymph node dissection (ALND) remains the standard approach for women who have clinically palpable axillary nodes. The benefits of ALND include its impact on disease control (axillary recurrence and survival), its prognostic value, and its role in treatment selection. However, the anatomic disruption caused by ALND may result in lymphedema, nerve injury, and shoulder dysfunction, which compromise functionality and quality of life. For patients who have clinically negative axillary lymph nodes, sentinel lymph node (SLN) biopsy offers a less morbid method to determine if there are positive nodes, in which case axillary node dissection would be necessary. Patients who are SLN-positive should undergo complete ALND. Axillary reverse mapping (ARM) is a recent improvement of ALND which, like the biopsy of the GS, would reduce morbidity. [less ▲]

Detailed reference viewed: 170 (9 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein de la femme âgée
MARTIN, Marie; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 400-408

Detailed reference viewed: 60 (6 ULg)
Full Text
Peer Reviewed
See detailTraitements ciblés dans le cancer du sein
JERUSALEM, Guy ULg; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 379-384

Detailed reference viewed: 73 (11 ULg)
Full Text
Peer Reviewed
See detailPrise en charge et suivi d'une série consécutive de 411 patientes opérées pour cancer du sein
LIFRANGE, Eric ULg; ANDRE, Chantal ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 329-335

Detailed reference viewed: 66 (9 ULg)
Full Text
Peer Reviewed
See detailChimiothérapie et cancer du sein
COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg; MARTIN, M. et al

in Revue Médicale de Liège (2011), 66(5-6), 372-378

Detailed reference viewed: 92 (17 ULg)
Full Text
Peer Reviewed
See detailHormonothérapie du cancer du sein
LIFRANGE, Eric ULg; ANDRE, Chantal ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 367-371

Detailed reference viewed: 140 (29 ULg)
Full Text
Peer Reviewed
See detailL'observance au traitement de longue durée : le cas particulier de l'hormonothérapie adjuvante du cancer du sein
Bleret, Valerie ULg; Collignon, Joëlle ULg; Coucke, Philippe ULg et al

in Revue Médicale de Liège (2010), 65(5-6), 405-408

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité ... [more ▼]

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité démontrée de l'hormonothérapie, la compliance constitue un défi majeur et un problème multidimensionnel. Une meilleure compréhension des raisons de cette non-compliance aiderait à mieux identifier les patientes à risque et à développer des interventions capables d'améliorer l'adhésion à l'hormonothérapie adjuvante.C'est dans ce but que nous avons entrepris une revue de la littérature des six dernières années (Pub Med 2003-2006). [less ▲]

Detailed reference viewed: 180 (28 ULg)
Full Text
Peer Reviewed
See detailANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques
Collignon, Joëlle ULg; Gennigens, Christine ULg; Rorive, Andrée ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 279-83

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of ... [more ▼]

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of targeted therapies in subgroups of cancers. One of the first validation of targeted therapy is the anti-HER-2 monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane domain and is only active in tumor with HER2 gene amplification detected by fluorescence in situ hybridization (FISH). The results from randomized trials have rapidly lead to the approvement of the drug in the metastatic and then in the adjuvant setting. Another targeted therapy, also approved in the treatment of breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular Endothelial Growth Factor) activity. We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer. [less ▲]

Detailed reference viewed: 477 (43 ULg)
Full Text
Peer Reviewed
See detailValidation de la technique de biopsie du ganglion sentinelle dans le cancer du sein
Bleret, Valerie ULg; Lifrange, Eric ULg; Ghuysen, Vincent ULg et al

in Revue Médicale de Liège (2008), 63(1), 37-42

PURPOSE: Assessment of our experience and validation of the sentinel lymph node biopsy technique in breast cancer stage T0-T2N0M0 surgery. METHODS: Identification and biopsy of the sentinel lymph node by ... [more ▼]

PURPOSE: Assessment of our experience and validation of the sentinel lymph node biopsy technique in breast cancer stage T0-T2N0M0 surgery. METHODS: Identification and biopsy of the sentinel lymph node by the radio colloid method in a consecutive series of 205 patients undergoing surgery for breast cancer stage T0-T2N0M0 between October 1998 and January 2007, initially in association with a complete axillary lymph node dissection (learning curve), later in an elective way. Prospective recording of the data and analysis with an average follow-up of 50 months (3 to 102 months). RESULTS: Biopsy rate of the sentinel lymph node of 90%, false negative rate of the method 2.5%, axillary recurrence rate 0%. CONCLUSION: We confirm in this series that the sentinel lymph node biopsy technique is a reliable approach in our experience for the evaluation of the axillary lymph node status in breast cancer stage T0-T2N0M0. [less ▲]

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailActualites therapeutiques en gynecologie: pathologies organiques
HERMAN, Philippe ULg; Lifrange, Eric ULg; Nisolle, Michelle ULg et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 414-22

Over the last ten years, progress in evidence-based medicine coupled with technological and surgical breakthroughs have deeply changed the management of our patients. Uterine bleeding is the first cause ... [more ▼]

Over the last ten years, progress in evidence-based medicine coupled with technological and surgical breakthroughs have deeply changed the management of our patients. Uterine bleeding is the first cause of gynaecological consultation and the intrauterine progestin delivery system as well as new hysteroscopic procedures have optimized the therapeutic approach to this problem. Introduction of magnetic resonance imaging and interventional procedures have improved breast disease diagnosis and management; likewise sentinel node localization, introduction of aromatase and growth factors inhibitors, new radiotherapy procedures and pharmacogenomics, have helped to ameliorate breast cancer treatment. Pelvic surgery has been switching more and more towards laparoscopic procedures not only in the field of benign lesions (eg endometriosis), of surgery of prolapse and incontinence with new prosthetic materials, but also for an improved management of gynaecological cancers. [less ▲]

Detailed reference viewed: 146 (7 ULg)
Full Text
Peer Reviewed
See detailDefining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer
BUDZAR, A.; CHLEBOWSKI, R.; CUZICK, J. et al

in Current Medical Research & Opinion (2006), 22

Detailed reference viewed: 12 (4 ULg)
Full Text
Peer Reviewed
See detailInteret et limites du depistage de masse du cancer du sein par mammographie seule (mammotest)
Lifrange, Eric ULg; Bleret, Valerie ULg; Desreux, Joëlle ULg et al

in Revue Médicale de Liège (2003), 58(5), 331-7

The literature on screening mammography provides ample opportunity for doubt (the sceptics) and dogma (the screening zealots), and can be interpreted to prove both benefit and harm. The benefit of ... [more ▼]

The literature on screening mammography provides ample opportunity for doubt (the sceptics) and dogma (the screening zealots), and can be interpreted to prove both benefit and harm. The benefit of mammography screening, if any, is modest and the balance between beneficial (potentially, a 20% relative reduction in breast cancer mortality with no significant benefit on all-cause mortality) and harmful (physical and psychological morbidity related to the 15-40% missed cancers and the 80-90% false-positive diagnoses) effects is still delicate. The mammogram alone is a modest weapon. Concurrent clinical breast examination is mandatory. Women that are concerned about breast cancer should be fully informed of the potential benefits and risks of screening mammography. These women should benefit from mammography with concurrent clinical breast examination, and possible whole-breast ultrasound in heterogeneously dense and extremely dense breast patterns. [less ▲]

Detailed reference viewed: 124 (14 ULg)
Full Text
Peer Reviewed
See detailHormonosubstitution postmenopausique et risque de cancer mammaire: une mise a jour
van den Brule, F.; Lifrange, Eric ULg; Pintiaux, Axelle ULg et al

in Revue Médicale de Liège (2003), 58(4), 254-60

Numerous studies have examined the risk of breast cancer in patients with postmenopausal hormone substitution. Most of these studies are retrospective, and a few recent studies are prospective. The ... [more ▼]

Numerous studies have examined the risk of breast cancer in patients with postmenopausal hormone substitution. Most of these studies are retrospective, and a few recent studies are prospective. The observed results present with weak variations from baseline and major heterogeneity. Some studies highlight a slightly increased relative risk of breast cancer. A reanalysis of 51 studies demonstrates a relative risk of 1.35 for developing breast cancer during hormone substitution, with a 2.3% increased risk per year of use. Recently, the results of the WHI study have shown a slight increase of some risks of disease, including breast cancer (relative risk, 1.26). These results have induced the interruption of one of the 3 arms of the study (that of the patients treated with an estrogen-progestin combination), and have provoked a new discussion about the benefits and risks associated with hormone substitution. These facts have been largely related and commented in the general press. In this article, we review the important studies concerning this topic. [less ▲]

Detailed reference viewed: 47 (4 ULg)
Full Text
Peer Reviewed
See detailTraitement hormonal apres cancer du sein. Oui ... ou non?
Foidart, Jean-Michel ULg; Desreux, Joëlle ULg; Lifrange, Eric ULg et al

in Revue Médicale de Liège (2003), 58(2), 77-82

Clinical and experimental studies indicate that combined unique conjugated estrogens and medroxyprogesterone acetate moderately increase the risk of breast cancer in postmenopausal women. Classically ... [more ▼]

Clinical and experimental studies indicate that combined unique conjugated estrogens and medroxyprogesterone acetate moderately increase the risk of breast cancer in postmenopausal women. Classically, hormone replacement therapy is contra-indicated in women with a past history of breast cancer due to the fear of recurrence. However, these postmenopausal patients complain about hot flushes and adjuvant hormonal therapies (such as aromatase inhibitors, SERMs and Tamoxifen...) aggravate their symptoms. Observational studies and their meta-analyses do not show a deleterious effect but rather a beneficial impact of hormone replacement therapy among women with a past history of breast cancer. We summarise all these studies and their biological, clinical and epidemiological interpretations. We conclude that short term hormone replacement therapy is safe among those women requesting a replacement therapy after complete information. It is however advisable to conclude definitely only when prospective randomised trials with estradiol or tibolone (a promising alternative) will be available. Such ongoing studies will allow to conclude definitely the possible benefits and risks of hormone replacement therapy among patients with a past history of breast cancer. [less ▲]

Detailed reference viewed: 124 (4 ULg)
Full Text
Peer Reviewed
See detailPercutaneous stereotactic en bloc excision of nonpalpable breast carcinoma: a step in the direction of supraconservative surgery
Lifrange, Eric ULg; Dondelinger, Robert ULg; Foidart, Jean-Michel ULg et al

in Breast (Edinburgh, Scotland ) (2002), 11(6), 501-508

Recently, the advanced breast biopsy instrumentation (ABBI) system has been introduced as an alternative to conventional breast biopsy techniques. This study was prospectively conducted to evaluate the ... [more ▼]

Recently, the advanced breast biopsy instrumentation (ABBI) system has been introduced as an alternative to conventional breast biopsy techniques. This study was prospectively conducted to evaluate the potential of the ABBI method in locoregional management of a consecutive series of patients with nonpalpable mammographically detected breast carcinomas. Sixty-one consecutive patients underwent an ABBI procedure as a first step before possible surgery for nonpalpable breast lesions that would in any case require complete excision. For the 27 patients in whom the ABBI biopsy revealed malignancy further surgery was recommended, including re-excision of the biopsy site and axillary dissection in cases of infiltrating carcinoma. We calculated the probabilities that the ABBI specimen would have tumor-free margins and that a definitely complete excision had been achieved as a function of the mammographic or pathological diameter of the cancer. For cancer with a pathological diameter less than 10 mm, measured on the ABBI specimen, the probability (92%) of obtaining complete resection was significantly better than for larger lesions (P = 0.01, Fisher's exact test). Although the therapeutic perspectives for the ABBI method are limited at present, we suggest that this approach is a first step in the direction of a surgical strategy that is better adapted to the pathological characteristics peculiar to these small tumors, whose incidence is increasing. (C) 2002 Elsevier Science Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 61 (11 ULg)